One of the big questions pharmaceutical, biotech and medical device companies often ask, is: “When is the optimal time to seek strategic regulatory consulting assistance?”. Traditionally, the need for regulatory consulting support is inversely proportional to the availability of expertise within the companies’ own regulatory department. This blog explains the three elements required for developing a successful regulatory strategy.
The below principles apply for three types of companies in particular. For companies in the drug development process, 50% requires a strategy at the project’s outset, and the rest tend to need a gap assessment, as filings are already in process. When you’re still early in the development process, considering multiple indications, the selection of the primary indication should be based on a number of viability factors, including commercial, scientific, regulatory, manufacturing, etc. For many companies considering numerous indications, the regulatory strategy will research the relative regulatory effort expected for each indication, to be considered with these other factors in selecting an initial indication. This will support decision making efforts. For emerging companies, a thorough strategy assessment not only includes a regulatory pathway but also provides assessments and plans for nonclinical, clinical and Chemistry Manufacturing and Controls (CMC). The objective of the regulatory strategy is to establish clarity on the optimal path to approval.
There are three elements necessary to develop a successful regulatory strategy:
The consultant must quickly become familiar with the client’s data, including:
- Product specifics and indications
- Nonclinical work that has been completed or planned
- Clinical work that has been completed or planned. (At this stage, clinical work may not have been completed in the US, but may exist in a different regulatory jurisdiction, e.g., EMA. Also, proof of concept data may exist).
- Manufacturing plans
- Business plans for the product
If possible, using prior approvals or relevant literature to make the case for safety and efficacy is optimal; this is particularly important for 505(b)(2) products. For novel products, FDA’s response to similar products may be instructive.
Successful strategies require input from experts in nonclinical, clinical, CMC and biopharmaceutics/pharmacology.
The development of a successful strategy typically takes about six to eight weeks to develop, discuss, and finalize. The strategy will typically include:
- Major regulatory milestones through approval
- Applicability of FDA’s Expedited Programs: Fast Track Designation, Breakthrough Therapy Designation, Accelerated Approval and Priority Review Designation
- Assessment of nonclinical work and recommended plans
- Clinical development plans
- Manufacturing/CMC plans including clinical supply and scale up for production
Once the strategy is established, the next step is typically the development and conduct of a Pre-IND Meeting. The objective of the strategy is to obtain internal alignment on the roadmap to approval. The objective of the Pre-IND Meeting is to align FDA with your strategy, compelling the Agency to provide responses to the client’s specific questions.
An investment in the development of a cogent regulatory strategy has the highest return on investment of any step in the drug development process; a well-designed strategy may enable you to eliminate certain nonclinical or clinical studies, thereby shortening development time and saving millions.
Are you in need of a solid regulatory strategy to guide your path to approval? We can help. Contact us today to learn how we can help develop a regulatory strategy for you, improving your chances of achieving successful interactions with FDA.